Premium
Transplantation of mesenchymal stem cells within a poly(lactide‐ co ‐ɛ‐caprolactone) scaffold improves cardiac function in a rat myocardial infarction model
Author(s) -
Jin Jiyong,
Jeong Sung In,
Shin Young Min,
Lim Kwang Suk,
Shin Heung soo,
Lee Young Moo,
Koh Hyun Chul,
Kim KyungSoo
Publication year - 2009
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1093/eurjhf/hfn017
Subject(s) - mesenchymal stem cell , transplantation , medicine , scaffold , ejection fraction , myocardial infarction , cardiac function curve , saline , tissue engineering , caprolactone , stem cell , cardiology , biomedical engineering , surgery , heart failure , pathology , microbiology and biotechnology , chemistry , biology , organic chemistry , copolymer , polymer
Aims Cardiac tissue engineering has been proposed as an appropriate method to repair myocardial infarction (MI). Evidence suggests that a cell with scaffold combination was more effective than a cell‐only implant. Nevertheless, to date, there has been no research into elastic biodegradable poly(lactide‐ co ‐ε‐caprolactone) (PLCL) scaffolds. The aim of this study was to investigate the effect of mesenchymal stem cells (MSCs) with elastic biodegradable PLCL scaffold transplants in a rat MI model. Methods and results Ten days after inducing MI through the cryoinjury method, a saline control, MSC, PLCL scaffold, or MSC‐seeded PLCL scaffold was transplanted onto the hearts. Four weeks after transplantation, cardiac function and histology were evaluated. Transplanted MSCs survived and differentiated into cardiomyocytes in the injured region. Left ventricular ejection fraction in the MSC + PLCL group increased by 23% compared with that in the saline group; it was also higher in the MSC group. The infarct area in the MSC + PLCL group was decreased by 29% compared with that in the saline group; it was also reduced in the MSC group. Conclusion Mesenchymal stem cells plus PLCL should be an excellent combination for cardiac tissue engineering.